SCHEDULE: Juvenescence Limited Increases Stake in Serina Therapeutics

Juvenescence Limited and its subsidiaries now beneficially own approximately 27.3% of Serina Therapeutics, Inc. following a recent private placement.

Summary

• Juvenescence Limited, along with its subsidiaries JuvVentures (UK) Limited and Juvenescence US Corp., has amended its Schedule 13D filing.
• The Reporting Persons collectively beneficially own 4,400,781 shares of Serina Therapeutics, Inc. Common Stock.
• This ownership represents approximately 27.3% of the Issuer's outstanding common stock.
• The calculation is based on 14,997,505 shares outstanding as of May 10, 2026, and includes shares from exercised warrants.
• The Reporting Persons did not participate in the recent private placement that occurred on March 20, 2026, which raised $15.0 million.
• This private placement resulted in a greater than 1% ownership change for the Reporting Persons.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on existing beneficial ownership and a non-participating role in a recent capital raise, without new strategic announcements or performance indicators.

Positives

• Juvenescence Limited has increased its beneficial ownership to 27.3% of Serina Therapeutics, Inc.
• The total number of shares beneficially owned is 4,400,781, comprising directly held shares and shares issuable upon warrant exercise.

Negatives

• The private placement on March 20, 2026, resulted in a dilution of ownership percentage for the Reporting Persons, despite their non-participation.
• The filing is an amendment, indicating ongoing changes in beneficial ownership and potential strategic shifts.

Risks

• The private placement may lead to further dilution if additional shares are issued.
• Changes in beneficial ownership can signal potential shifts in control or strategic direction, which may not align with all stakeholders' interests.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from management regarding future performance. It primarily details current beneficial ownership and recent transactions.

Industry Context

StockSavvy.ai notes that significant shifts in beneficial ownership, especially those exceeding 5% or involving activist investors, are common in the biotechnology sector as companies advance drug candidates or face strategic decisions. This filing indicates a substantial, ongoing interest from Juvenescence Limited in Serina Therapeutics.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by Juvenescence Limited may signal a potential for greater influence on corporate strategy or future actions.
• Investors: The filing provides transparency on significant ownership stakes, aiding investment decisions.
• Management: The non-participation in the private placement by Juvenescence Limited might indicate strategic considerations or a focus on existing holdings.

Next Steps

• Monitoring future filings from Juvenescence Limited and Serina Therapeutics for any changes in ownership or strategic direction.
• Observing the impact of the recent private placement on Serina Therapeutics' financial position and operational plans.

Key Dates

Recommendation

The filing indicates a significant and stable beneficial ownership by Juvenescence Limited, but it does not present new information that would warrant a change in investment strategy. The non-participation in the recent private placement suggests a cautious approach rather than an aggressive one, making 'hold' appropriate pending further developments.

Keywords

Serina Therapeutics, Juvenescence Limited, Schedule 13D, Beneficial Ownership, Common Stock, Warrants, Private Placement, Shareholder